The VEGF Polyclonal Antibody (CAB16703) is specifically designed for research involving vascular endothelial growth factor (VEGF), a key protein involved in the regulation of blood vessel formation and angiogenesis. This antibody, raised in rabbits, has high reactivity with human samples and is validated for use in various applications including Western blot and immunohistochemistry.VEGF is a critical player in angiogenesis, the process of forming new blood vessels from pre-existing ones, which is essential for normal development, wound healing, and disease progression, including cancer. By targeting VEGF, researchers can gain insights into the mechanisms underlying angiogenesis and potentially develop therapies to target this pathway in diseases such as cancer, diabetic retinopathy, and cardiovascular disorders.
This polyclonal antibody binds specifically to VEGF, allowing for the detection and analysis of VEGF expression in different cell types and tissues. Its versatility and high specificity make it an invaluable tool for investigations in vascular biology, oncology, and pharmacology. Understanding the role of VEGF in angiogenesis is crucial for developing targeted therapies that can inhibit or stimulate blood vessel growth in various pathological conditions.
Product Name:
VEGF Rabbit Polyclonal Antibody
SKU:
CAB16703
Size:
20uL, 100uL
Isotype:
IgG
Host Species:
Rabbit
Reactivity:
Human,Mouse,Rat
Immunogen:
Recombinant fusion protein containing a sequence corresponding to amino acids 91-191 of human VEGFA (NP_001165097.1).
This gene is a member of the PDGF/VEGF growth factor family. It encodes a heparin-binding protein, which exists as a disulfide-linked homodimer. This growth factor induces proliferation and migration of vascular endothelial cells, and is essential for both physiological and pathological angiogenesis. Disruption of this gene in mice resulted in abnormal embryonic blood vessel formation. This gene is upregulated in many known tumors and its expression is correlated with tumor stage and progression. Elevated levels of this protein are found in patients with POEMS syndrome, also known as Crow-Fukase syndrome. Allelic variants of this gene have been associated with microvascular complications of diabetes 1 (MVCD1) and atherosclerosis. Alternatively spliced transcript variants encoding different isoforms have been described. There is also evidence for alternative translation initiation from upstream non-AUG (CUG) codons resulting in additional isoforms. A recent study showed that a C-terminally extended isoform is produced by use of an alternative in-frame translation termination codon via a stop codon readthrough mechanism, and that this isoform is antiangiogenic. Expression of some isoforms derived from the AUG start codon is regulated by a small upstream open reading frame, which is located within an internal ribosome entry site. The levels of VEGF are increased during infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), thus promoting inflammation by facilitating recruitment of inflammatory cells, and by increasing the level of angiopoietin II (Ang II), one of two products of the SARS-CoV-2 binding target, angiotensin-converting enzyme 2 (ACE2). In turn, Ang II facilitates the elevation of VEGF, thus forming a vicious cycle in the release of inflammatory cytokines.
Purification Method:
Affinity purification
Gene ID:
7422
Storage Buffer:
Store at -20℃. Avoid freeze / thaw cycles.Buffer: PBS with 0.01% thimerosal,50% glycerol,pH7.3.
Western blot analysis of various lysates using VEGFA Rabbit pAb (CAB16703) at 1:1000 dilution.Secondary antibody: HRP Goat Anti-Rabbit IgG (H+L) (CABS014) at 1:10000 dilution.Lysates/proteins: 25μg per lane.Blocking buffer: 3% nonfat dry milk in TBST.Detection: ECL Basic Kit (AbGn00020).Exposure time: 1s.
